Effectiveness of Group Based Schema Therapy in the Treatment of Personality Disorders

Personality Disorder, Borderline Clinical Trial

Official title:

Effectiveness of Group Based Schema Therapy in the Treatment of Borderline Personality Disorder and Avoidant Personality Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00247234
• Other study ID #: ursula.falkmer+AEA-stolav.no
• Status: Completed
• Phase: N/A
• First received: October 31, 2005
• Last updated: September 20, 2017
• Start date: September 2004
• Est. completion date: January 2015

Study information

• Verified date: September 2017
• Source: Norwegian University of Science and Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study intends to compare the effectiveness of schema therapy with standard psychiatric outpatient care for patients with borderline or avoidant personality disorder.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: January 2015
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• Avoidant or Borderline personality disorders

Exclusion Criteria:

• Do not speak Scandinavian languages

• Antisocial personality disorder

• Narcissistic personality disorder

• Affective bipolar disorder I

• Schizophrenia

• Mental impairment/organic brain disorder

• Substance dependence

• Planned pregnancy

• Serious somatic illness

• Anorexia Nervosa

Related Conditions & MeSH terms

• Avoidant Personality Disorder
• Borderline Personality Disorder
• Disease
• Personality Disorder, Borderline
• Personality Disorders

Intervention

Behavioral:
• Schema Therapy
group based schema therapy
• standard care
standard psychiatric out-patient care

Locations

Country	Name	City	State
Norway	St. Olavs Hospital	Trondheim

Sponsors (1)

Lead Sponsor	Collaborator
Norwegian University of Science and Technology

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	quality of life	Self-report measures	5 years
Primary	depression	Self-report measures	5 years
Primary	anxiety	Self-report measures	5 years
Primary	suicidal ideation	Self-report measures	5 years
Secondary	Use of psychotropic medication		5 years